Fly News Breaks for February 7, 2020
Feb 7, 2020 | 05:32 EDT
Piper Sandler analyst Danielle Brill says the selloff in shares of Zogenix (ZGNX) following last night's Phase 3 data of Fintepla in Lennox-Gastaut syndrome is overdone. The study hit its primary efficacy endpoint of reduction in monthly drop seizures from baseline vs placebo, but the placebo-adjusted impact on drop seizures was marginally worse than GW Pharmaceuticals's (GWPH) Epidiolex and the proportion of patients with greater than 50% reduction in drop seizure frequency compared even less favorably to its competitor, Brill tells investors in a research note. That said, the trial was still positive and with the stock indicating being down ~35%, the selloff is overdone, contends the analyst. She keeps an Overweight rating on Zogenix with a $64 price target.
News For ZGNX;GWPH From the Last 2 Days
Apr 14, 2021 | 08:12 EDT
Stifel analyst Annabel Samimy raised the firm's price target on Jazz Pharmaceuticals (JAZZ) to $202 from $195 and keeps a Buy rating on the shares following checks with legal and seizure key opinion leaders. Samimy thinks the addition of GW Pharmaceuticals' (GWPH) Epidiolex for rare childhood epilepsies accelerates Jazz's diversification plan and "offers another sizable avenue of growth," the analyst tells investors.